Retatrutide Hits 25% Weight Loss in Phase 3 Trial, And the Numbers Keep Climbing

An experimental weekly injection just moved the goalposts. The question is whether anyone can actually get it.

Eli Lilly dropped the full Phase 3 data on retatrutide. The numbers landed. And they landed hard.

At the highest dose, 12 milligrams, participants lost an average of 25 percent of their starting body weight after 80 weeks. In the extension study, that number climbed to nearly 30 percent after two years. More than a third of patients on the top dose lost at least 25 percent of their body weight. Fifty-two percent lost at least 20 percent.

This is not a modest improvement over what's already on the shelf. This is a different category of result.

But here's the thing about averages. They hide the individual. Someone in that trial lost more. Someone lost less. The drug doesn't work the same way for every body. And the drug is not available yet. Not anywhere legal.

Still. The data is the data. And this data matters.

What Just Happened

The trial is called TRIUMPH-1. It enrolled 2,339 adults with obesity but without diabetes. Participants were randomly assigned to weekly injections of 4, 9, or 12 milligrams of retatrutide, or a placebo. Neither the participants nor the investigators knew who got what.

After 80 weeks, the average weight reductions looked like this:

• 4 mg dose: 17.6% weight loss
• 9 mg dose: 23.7% weight loss
• 12 mg dose: 25% weight loss
• Placebo: 3.9% weight loss

Those calculations accounted for people who stopped treatment or started other weight-management therapies. In other words, they're conservative. They don't cherry-pick the successes.

The 9-milligram group lost an average of 64.4 pounds. The 12-milligram group lost an average of 70.3 pounds. That's 28.3 percent for the 12-milligram arm in the per-protocol analysis.

And the weight loss didn't plateau. Participants kept losing through the full 80 weeks. No ceiling. No stall. That's unusual.

How Retatrutide Works

Most weight loss drugs on the market target one hormone. Wegovy and Ozempic hit GLP-1. Zepbound hits GLP-1 and GIP. Retatrutide hits three.

The drug activates receptors for GLP-1, GIP, and glucagon.

GLP-1 regulates appetite and triggers insulin release when blood sugar rises. GIP supports the insulin response after eating. Glucagon helps the liver release glucose, and activating its receptor can also increase energy expenditure.

The idea is simple. Combine effects that reduce food intake with effects that increase energy use. Earlier experiments in mice linked this combination to both lower food consumption and higher energy expenditure.

This trial examined clinical outcomes rather than measuring each pathway's contribution separately. The researchers didn't isolate which receptor did what. They just measured what happened to the people.

What happened was significant weight loss, reduced knee pain, and fewer sleep apnea events.

The Results Beyond the Scale

The researchers tracked more than kilograms lost. They also examined knee pain and breathing disruptions during sleep.

Knee pain decreased more than with placebo. Sleep apnea events decreased more than with placebo. These are not cosmetic outcomes. These are quality-of-life outcomes. A flight of stairs becomes a challenge for aching knees. Sleep gets broken by repeated breathing problems. For people living with obesity, the effects of the disease reach far beyond the number on a bathroom scale.

The trial also tracked cardiovascular risk factors. At the top dose, average reductions were 39.5 percent in triglycerides, 19.6 percent in non-HDL cholesterol, 10.8 mmHg in systolic blood pressure, and 58.3 percent in high-sensitivity C-reactive protein.

Those numbers matter. They point toward a drug that does more than shrink a waistline. They point toward a drug that might change metabolic health in ways that ripple outward.

In the extension study, 532 participants who completed the 80-week treatment period continued for another 24 weeks. Those originally on 12 milligrams continued at a maximum tolerated dose of 9 or 12 milligrams. In this group, average weight loss reached 29.9 percent after 104 weeks.

For participants with a baseline BMI of 35 or higher who stayed on the 12-milligram dose through 104 weeks, average weight loss hit 30.3 percent, 85 pounds.

That's approaching what bariatric surgery achieves. Not matching it. Approaching it.

Retatrutide vs. Ozempic vs. Zepbound

People want a scoreboard. They want to know which drug wins.

The honest answer is that no head-to-head trial exists between retatrutide and Ozempic. None. The comparisons floating around the internet are cross-trial comparisons. Those are useful for context. They are not proof of superiority.

Here's what we know from separate trials.

Ozempic, semaglutide, produces roughly 14 to 15 percent average weight loss in obesity trials. Wegovy, the same drug at a higher dose for weight management, does a bit better. Zepbound, tirzepatide, produces around 20 to 22 percent average weight loss in its pivotal trials.

In a head-to-head Phase 3 trial called REDEFINE 4, Novo Nordisk's CagriSema achieved 23 percent weight loss after 84 weeks. Zepbound achieved 25.5 percent in the same trial. CagriSema didn't beat Zepbound. That was a setback for Novo.

Retatrutide's 25 percent at 80 weeks sits in a different territory. But again, different trial, different population, different protocol. The TRIUMPH-1 population had obesity without diabetes. The REDEFINE 4 population included people with type 2 diabetes, whose weight loss tends to be more difficult.

Comparing these numbers directly is like comparing a marathon time from a flat course to one from a hilly course. The distance is the same. The terrain is not.

What retatrutide does offer is a triple mechanism. Zepbound hits two receptors. Ozempic hits one. The glucagon component in retatrutide may contribute to sustained metabolic activation that dual-agonist approaches don't produce.

That's a hypothesis. The trial didn't prove it. But the lack of a weight loss plateau suggests something different is happening.

When Can You Get It?

Not now. Not soon.

Eli Lilly plans to file for FDA approval of retatrutide in the first quarter of next year. The FDA review process takes months. Even under accelerated timelines, the drug is unlikely to hit pharmacies before late 2027 or early 2028.

And when it does arrive, access will be a problem. The same problem that plagued Ozempic and Wegovy. Insurance coverage. Supply constraints. Price tags that make people gasp.

There's another problem. People are already searching for retatrutide on grey markets. Searches for the experimental peptide have soared over 1,200 percent in the past year. The drug isn't approved anywhere. It isn't legally available anywhere. But people are buying it from unregulated suppliers and injecting it into their bodies.

That's a risk. An unregulated peptide is not the same as a pharmaceutical-grade medication. The purity is uncertain. The dosing is guesswork. The side effects, from something that hasn't been through the full regulatory gauntlet, are unknown.

The trial data is promising. The grey market is not.

What This Means

Obesity is a disease. That's not a political statement. That's a medical one. The American Medical Association recognized it as such in 2013. The World Health Organization classified it as a chronic condition.

But the treatment landscape has been grim for decades. Diet and exercise. Willpower. Shame. The implication that people who carry extra weight simply lack discipline.

GLP-1 drugs changed that narrative. They showed that biology matters. Hormones matter. The brain's regulation of appetite matters. Retatrutide pushes that understanding further. It suggests that targeting multiple biological pathways produces results that single-pathway drugs can't touch.

This doesn't mean the drug is a miracle. It doesn't mean it's safe for everyone. It doesn't mean it's a replacement for surgery or lifestyle changes or whatever else people do to manage their health. It means there's another option coming. Another tool in a toolbox that has been embarrassingly empty for a long time.

The side effects are consistent with the GLP-1 class. Nausea. Vomiting. Diarrhea. The usual gastrointestinal discomfort that makes people question whether the trade-off is worth it. For some, it will be. For others, it won't. The drugmaker noted a safety profile consistent with other GLP-1 therapies.

The trial results don't answer every question. They don't tell us what happens after five years. They don't tell us whether the weight stays off when the injections stop. They don't tell us whether the cardiovascular benefits translate into fewer heart attacks and strokes.

Those studies are ongoing. Or they will be.

Retatrutide delivered 25 percent weight loss at 80 weeks in a Phase 3 trial. Nearly 30 percent at two years. More than a third of patients on the top dose lost at least a quarter of their body weight.

The drug is not available. It won't be for a while. When it is, it will be expensive and hard to get. People will struggle with insurance. People will struggle with supply. People will buy it from questionable sources and hope for the best.

The data is real. The hope is real. The frustration of waiting is real too.

If you're looking for weight loss treatment right now, talk to a doctor about what's actually available. Ozempic. Wegovy. Zepbound. These drugs work. They're approved. They're prescribed every day. Retatrutide is coming. It's not here yet.

The goalposts moved. The game is still the same. You still have to navigate the system. You still have to find a doctor who listens. You still have to figure out what works for your body and your life.

The drug helps. The drug doesn't do everything. That's the truth nobody wants to print on the box.